Background Respiratory syncytial virus (RSV) is the most common cause of lower
respiratory tract infection in infants, and a need exists for prevention of RSV in healthy …

Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV …

Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract …

Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting …

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the
United States. In August 2023, CDC's Advisory Committee on Immunization Practices …

Nirsevimab for Prevention of RSV Nirsevimab is a monoclonal antibody targeting respiratory
syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to …

Background In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-
life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants …

Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting …

Nirsevimab (Beyfortus®), a long-acting intramuscular recombinant neutralising human
IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus …